Factors influencing patient preferences for obesity pharmacotherapy: The triangulation of semi-structured interviews, photovoice study and focus group discussions. [PDF]
Obes PillarsMondoh A +4 more
europepmc +1 more source
A glimpse into the pipeline of anti-obesity medication development: combining multiple receptor pathways. [PDF]
Front Endocrinol (Lausanne)Park C, Kim Y, Raygani S, Grunvald E.
europepmc +1 more source
Brain Amylin Signaling, Feeding, and Reward. [PDF]
Compr PhysiolMietlicki-Baase EG.
europepmc +1 more source
Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review. [PDF]
World J GastroenterolConcepción-Zavaleta MJ +9 more
europepmc +1 more source
An Overview of Existing and Emerging Weight-Loss Drugs to Target Obesity-Related Complications: Insights from Clinical Trials. [PDF]
Biomol Ther (Seoul)Kim MK, Kim HS.
europepmc +1 more source
Restructuring the Obesity Paradigm: Molecular Etiologies, Clinical Complexities, and the Future of Precision Intervention. [PDF]
CureusLatt TS +5 more
europepmc +1 more source
Incretin-based cardiovascular protection beyond diabetes: evidence, mechanisms, and therapeutic frontiers from GLP-1 receptor agonists to multi-agonist therapy. [PDF]
Front Endocrinol (Lausanne)Qiu L, Liu J, Hu N.
europepmc +1 more source
An Overview of Currently Available Injectable Therapies in Diabetes: A Guide to Practitioners. [PDF]
Adv TherKesavadev J +9 more
europepmc +1 more source
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases. [PDF]
Nephrol Dial TransplantApperloo EM +3 more
europepmc +1 more source
The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies. [PDF]
Biosci RepPatil M +4 more
europepmc +1 more source